Recruiting
Phase 2

89Zr-girentuximab for PET Imaging of CAIX Positive Solid Tumors

Sponsor:

Telix Pharmaceuticals (Innovations) Pty Limited

Code:

NCT05563272

Conditions

Cervical Cancer

Colorectal Cancer

Esophageal Cancer

Gastric Cancer

Glioblastoma Multiforme

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

89Zr-DFO-girentuximab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information